CN Patent

CN116421554A — 尼莫地平注射液及其制备方法

Assigned to Hubei Huaren Tongji Pharmaceutical Co ltd · Expires 2023-07-14 · 3y expired

What this patent protects

本发明涉及一种尼莫地平注射液及其制备方法，由尼莫地平、琥珀酸、环拉酸钠、乙醇、pH调节剂、注射用水组成。采用琥珀酸、环拉酸钠、乙醇作为尼莫地平注射液的辅料，在完全溶解尼莫地平的情况下，相比于现有技术极大地减少了乙醇的用量，并且无需使用其他助溶剂。此外，所得尼莫地平注射液的稳定性也得到显著的改善。

USPTO Abstract

本发明涉及一种尼莫地平注射液及其制备方法，由尼莫地平、琥珀酸、环拉酸钠、乙醇、pH调节剂、注射用水组成。采用琥珀酸、环拉酸钠、乙醇作为尼莫地平注射液的辅料，在完全溶解尼莫地平的情况下，相比于现有技术极大地减少了乙醇的用量，并且无需使用其他助溶剂。此外，所得尼莫地平注射液的稳定性也得到显著的改善。

Drugs covered by this patent

Caduet (Amlodipine Besylate) · Pfizer Inc.

Patent Metadata

Patent number: CN116421554A
Jurisdiction: CN
Classification: —
Expires: 2023-07-14
Drug substance claim: No
Drug product claim: No
Assignee: Hubei Huaren Tongji Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.